ISBN: 978-1-4731-3093-7 Study Intervention and comparison Population Outcomes Comments Stroke Subsequent procedures CABG Subsequent procedures PCI No. in NYHA Class I Treating Heart Failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 6.3.1.3.1 CABG versus medical therapy Table 70: Clinical evidence summary: CABG + Medical therapy versus medical therapy Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relativ e effect CI) Anticipated absolute effects Risk with medical therapy Risk difference with CABG (95% CI) All-cause mortality 1212 MODERATEa due to risk of bias (from 27 fewer to 130 fewer) All-cause mortality at 30 days 1212 MODERATEa due to risk of bias (from 4 more to 70 more) Quality of life - EQ-5D Scale from: 0 to 1. LOWa,b due to risk of bias, imprecision The mean quality of life EQ-5D at 12 months in the control groups was The mean quality of life EQ-5D at 12 months in the intervention groups was Quality of life - EQ5D-VAS Scale from: 0 to 100 MODERATEa due to risk of bias The mean quality of life - EQ5D-VAS in the control groups was The mean quality of life - EQ5D-VAS in the intervention groups was Quality of life KCCQ (quality of life domain) Scale from: 0 to 100. 